Roth Capital Maintains Buy On ImmunoCellular Following 3Q:14 Update
Roth Capital analyst Joseph Pantginis maintained a Buy rating on ImmunoCellular Therapeutics (NYSE:IMUC) with a price target of $3.00, following the company’s third-quarter report, posting EPS of ($0.03) vs. Roth’s estimate of ($0.06).
Pantginis noted, “We reiterate our positive view on the current efforts IMUC management is doing to advance its three clinical programs forward and in particular ICT-107 with its planned Phase III study expected to begin next year. Recall that key outcomes from the FDA meeting are: 1) targeting of only HLA-A2 patients and 2) stratifying MGMT status within one study or two separate trials is acceptable. In the event of two separate studies, the FDA stated that either study would be sufficient for BLA filing (with the Phase II data). Of note, ICT-107 is the only therapy which has shown a clinical benefit in unmethylated MGMT status patients.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -4.9% and a 45.6% success rate. Pantginis has a -43.8% average return when recommending IMUC, and is ranked #3285 out of 3367 analysts.